

David J Timson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2867108/publications.pdf>

Version: 2024-02-01

182
papers

4,940
citations

94433

37
h-index

128289

60
g-index

186
all docs

186
docs citations

186
times ranked

5140
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression, purification and crystallization of a novel metagenome-derived salicylaldehyde dehydrogenase from Alpine soil. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2022, 78, 161-169.	0.8	0
2	Targeting HIF-1 α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1. <i>Journal of Personalized Medicine</i> , 2022, 12, 747.	2.5	12
3	L-Asparaginase from <i>Penicillium sizovae</i> Produced by a Recombinant <i>Komagataella phaffii</i> Strain. <i>Pharmaceuticals</i> , 2022, 15, 746.	3.8	5
4	The structural and molecular biology of type IV galactosemia. <i>Biochimie</i> , 2021, 183, 13-17.	2.6	10
5	Galactokinase deficiency: lessons from the GalNet registry. <i>Genetics in Medicine</i> , 2021, 23, 202-210.	2.4	14
6	[13 C]-galactose breath test in a patient with galactokinase deficiency and spastic diparesis. <i>JIMD Reports</i> , 2021, 59, 104-109.	1.5	0
7	Galactosemia: Towards Pharmacological Chaperones. <i>Journal of Personalized Medicine</i> , 2021, 11, 106.	2.5	12
8	New model for the interaction of IQGAP1 with CDC42 and RAC1. <i>Small GTPases</i> , 2020, 11, 16-22.	1.6	17
9	RNA interference dynamics in juvenile <i>Fasciola hepatica</i> are altered during in vitro growth and development. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2020, 14, 46-55.	3.4	4
10	Yeast Cellular Stress: Impacts on Bioethanol Production. <i>Fermentation</i> , 2020, 6, 109.	3.0	24
11	Pilot Evaluation of Two <i>Fasciola hepatica</i> Biomarkers for Supporting Triclabendazole (TCBZ) Efficacy Diagnostics. <i>Molecules</i> , 2020, 25, 3477.	3.8	1
12	Destressing Yeast for Higher Biofuel Yields: Can Excess Chaotropicity Be Mitigated?. <i>Applied Biochemistry and Biotechnology</i> , 2020, 192, 1368-1375.	2.9	1
13	The Catalytic Cycle of the Antioxidant and Cancer-Associated Human NQO1 Enzyme: Hydride Transfer, Conformational Dynamics and Functional Cooperativity. <i>Antioxidants</i> , 2020, 9, 772.	5.1	22
14	In Silico Analysis of the Effects of Point Mutations on β -Globin: Implications for β -Thalassemia. <i>Hemoglobin</i> , 2020, 44, 89-103.	0.8	1
15	In silico analysis of the effects of disease-associated mutations of β 2-hexosaminidase A in Tayâ€™Sachs disease. <i>Journal of Genetics</i> , 2020, 99, 1.	0.7	3
16	The roles and applications of chaotropes and kosmotropes in industrial fermentation processes. <i>World Journal of Microbiology and Biotechnology</i> , 2020, 36, 89.	3.6	14
17	Novel and selective inactivators of Triosephosphate isomerase with anti-trematode activity. <i>Scientific Reports</i> , 2020, 10, 2587.	3.3	12
18	The <i>Schistosoma mansoni</i> tegumental allergen protein, SmTAL1: Binding to an IQ-motif from a voltage-gated ion channel and effects of praziquantel. <i>Cell Calcium</i> , 2020, 86, 102161.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Galactosemia: opportunities for novel therapies. , 2020, , 221-245.		2
20	The Mechanism of Action of Praziquantel: Can New Drugs Exploit Similar Mechanisms?. Current Medicinal Chemistry, 2020, 27, 676-696.	2.4	26
21	Therapies for galactosemia: a patent landscape. Pharmaceutical Patent Analyst, 2020, 9, 45-51.	1.1	8
22	Praziquantel: An Enigmatic, Yet Effective, Drug. Methods in Molecular Biology, 2020, 2151, 1-8.	0.9	4
23	analysis of the effects of disease-associated mutations of β -hexosaminidase A in Tay-Sachs disease. Journal of Genetics, 2020, 99, .	0.7	0
24	Repurposing drugs for the treatment of galactosemia. Expert Opinion on Orphan Drugs, 2019, 7, 443-451.	0.8	3
25	A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer. Biomolecules, 2019, 9, 728.	4.0	21
26	Dynamic origins of substrate promiscuity in bacterial galactokinases. Carbohydrate Research, 2019, 486, 107839.	2.3	2
27	Evidence for chaotropicity/kosmotropicity offset in a yeast growth model. Biotechnology Letters, 2019, 41, 1309-1318.	2.2	8
28	Characterization of Calcium-Binding Proteins from Parasitic Worms. Methods in Molecular Biology, 2019, 1929, 615-641.	0.9	0
29	Catalytic mechanism of mevalonate kinase revisited, a QM/MM study. Organic and Biomolecular Chemistry, 2019, 17, 2423-2431.	2.8	8
30	Escherichia coli Modulator of Drug Activity B (MdaB) Has Different Enzymological Properties to Eukaryote Quinone Oxidoreductases. Helvetica Chimica Acta, 2019, 102, e1900135.	1.6	0
31	Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1). ChemBioChem, 2019, 20, 2841-2849.	2.6	16
32	NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 663-676.	2.3	68
33	Four Challenges for Better Biocatalysts. Fermentation, 2019, 5, 39.	3.0	17
34	Phosphorylation Mechanism of <i>N</i> -Acetyl-L-glutamate Kinase, a QM/MM Study. Journal of Physical Chemistry B, 2019, 123, 2844-2852.	2.6	3
35	Myosin Va and spermine synthase: partners in exosome transport. Bioscience Reports, 2019, 39, .	2.4	3
36	Fructose 1,6-bisphosphatase: getting the message across. Bioscience Reports, 2019, 39, .	2.4	25

#	ARTICLE	IF	CITATIONS
37	Type IV galactosemia. <i>Genetics in Medicine</i> , 2019, 21, 1283-1285.	2.4	12
38	NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places. <i>Bioscience Reports</i> , 2019, 39, .	2.4	55
39	Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity. <i>Bioscience Reports</i> , 2019, 39, .	2.4	7
40	The tegumental allergen-like proteins of <i>Schistosoma mansoni</i> : A biochemical study of SmTAL4-TAL13. <i>Molecular and Biochemical Parasitology</i> , 2018, 221, 14-22.	1.1	11
41	Improving the Activity and Stability of Human Galactokinase for Therapeutic and Biotechnological Applications. <i>ChemBioChem</i> , 2018, 19, 1088-1095.	2.6	8
42	Modulation of the mobility of a key region in human galactokinase: Impacts on catalysis and stability. <i>Bioorganic Chemistry</i> , 2018, 81, 649-657.	4.1	2
43	Calmodulins from <i>Schistosoma mansoni</i> : Biochemical analysis and interaction with IQ-motifs from voltage-gated calcium channels. <i>Cell Calcium</i> , 2018, 74, 1-13.	2.4	6
44	A galactokinase-like protein from the liver fluke <i>Fasciola hepatica</i> . <i>Experimental Parasitology</i> , 2018, 192, 65-72.	1.2	0
45	Water-mediated network in the resistance mechanism of fosfomycin. <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 21660-21667.	2.8	3
46	The Mechanism of Action of Praziquantel: Six Hypotheses. <i>Current Topics in Medicinal Chemistry</i> , 2018, 18, 1575-1584.	2.1	31
47	Different specificities of two aldehyde dehydrogenases from <i>Saccharomyces cerevisiae</i> var. <i>boulardii</i> . <i>Bioscience Reports</i> , 2017, 37, .	2.4	12
48	In silico prediction of the effects of mutations in the human triose phosphate isomerase gene: Towards a predictive framework for TPI deficiency. <i>European Journal of Medical Genetics</i> , 2017, 60, 289-298.	1.3	7
49	Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism. <i>Scientific Reports</i> , 2017, 7, 44532.	3.3	35
50	Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 245, 155-190.	1.8	10
51	Enhanced vulnerability of human proteins towards disease-associated inactivation through divergent evolution. <i>Human Molecular Genetics</i> , 2017, 26, 3531-3544.	2.9	34
52	Characterisation of eppin function: expression and activity in the lung. <i>European Respiratory Journal</i> , 2017, 50, 1601937.	6.7	5
53	LGR5 receptor promotes cell-cell adhesion in stem cells and colon cancer cells via the IQGAP1-Rac1 pathway. <i>Journal of Biological Chemistry</i> , 2017, 292, 14989-15001.	3.4	57
54	Reaction Mechanism of Isopentenyl Phosphate Kinase: A QM/MM Study. <i>Journal of Physical Chemistry B</i> , 2017, 121, 11062-11071.	2.6	9

#	ARTICLE	IF	CITATIONS
55	Antioxidant properties and global metabolite screening of the probiotic yeast <i>Saccharomyces cerevisiae</i> var. <i>boulardii</i> . <i>Journal of the Science of Food and Agriculture</i> , 2017, 97, 3039-3049.	3.5	43
56	Insight into the mechanism of galactokinase: Role of a critical glutamate residue and helix/coil transitions. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 321-328.	2.3	10
57	Modulating Mobility: a Paradigm for Protein Engineering?. <i>Applied Biochemistry and Biotechnology</i> , 2017, 181, 83-90.	2.9	11
58	Glycerol enhances fungal germination at the water activity limit for life. <i>Environmental Microbiology</i> , 2017, 19, 947-967.	3.8	52
59	Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism. <i>Current Drug Targets</i> , 2017, 18, 500-510.	2.1	41
60	IQGAP1 Interaction with RHO Family Proteins Revisited. <i>Journal of Biological Chemistry</i> , 2016, 291, 26364-26376.	3.4	26
61	<i>Fasciola hepatica</i> calcium-binding protein FhCaBP2: structure of the dynein light chain-like domain. <i>Parasitology Research</i> , 2016, 115, 2879-2886.	1.6	7
62	Galactokinase promiscuity: a question of flexibility?. <i>Biochemical Society Transactions</i> , 2016, 44, 116-122.	3.4	14
63	Phosphorylation Mechanism of Phosphomevalonate Kinase: Implications for Rational Engineering of Isoprenoid Biosynthetic Pathway Enzymes. <i>Journal of Physical Chemistry B</i> , 2016, 120, 10714-10722.	2.6	8
64	A mysterious family of calcium-binding proteins from parasitic worms. <i>Biochemical Society Transactions</i> , 2016, 44, 1005-1010.	3.4	16
65	Characterization of Cd36_03230p, a putative vanillin dehydrogenase from <i>Candida dubliniensis</i> . <i>RSC Advances</i> , 2016, 6, 99774-99780.	3.6	4
66	FhCaBP1 (FH22): A <i>Fasciola hepatica</i> calcium-binding protein with EF-hand and dynein light chain domains. <i>Experimental Parasitology</i> , 2016, 170, 109-115.	1.2	7
67	Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands. <i>Scientific Reports</i> , 2016, 6, 20331.	3.3	39
68	Calmodulin disruption impacts growth and motility in juvenile liver fluke. <i>Parasites and Vectors</i> , 2016, 9, 46.	2.5	21
69	Experimental and computational evidence on conformational fluctuations as a source of catalytic defects in genetic diseases. <i>RSC Advances</i> , 2016, 6, 58604-58612.	3.6	8
70	Disturbed cofactor binding by a novel mutation in UDP-galactose 4-epimerase results in a type III galactosemia phenotype at birth. <i>RSC Advances</i> , 2016, 6, 17297-17301.	3.6	2
71	The molecular basis of galactosemia – Past, present and future. <i>Gene</i> , 2016, 589, 133-141.	2.2	66
72	On the Interaction Between Human IQGAP1 and Actin. <i>Protein and Peptide Letters</i> , 2016, 23, 386-395.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets. <i>Current Protein and Peptide Science</i> , 2016, 17, 280-295.	1.4	17
74	Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms. <i>Current Drug Targets</i> , 2016, 17, 1506-1514.	2.1	31
75	FhCaBP2: a <i>Fasciola hepatica</i> calcium-binding protein with EF-hand and dynein light chain domains. <i>Parasitology</i> , 2015, 142, 1375-1386.	1.5	10
76	<i>In Silico</i> Prediction of the Effects of Mutations in the Human Mevalonate Kinase Gene: Towards a Predictive Framework for Mevalonate Kinase Deficiency. <i>Annals of Human Genetics</i> , 2015, 79, 451-459.	0.8	21
77	Quantitative Enzymology. <i>Current Enzyme Inhibition</i> , 2015, 11, 12-31.	0.4	9
78	UDP-galactose 4-epimerase from the liver fluke, <i>Fasciola hepatica</i> : biochemical characterization of the enzyme and identification of inhibitors. <i>Parasitology</i> , 2015, 142, 463-472.	1.5	6
79	Is there a common water-activity limit for the three domains of life?. <i>ISME Journal</i> , 2015, 9, 1333-1351.	9.8	229
80	Comparative biochemical analysis of three members of the <i>Schistosoma mansoni</i> TAL family: Differences in ion and drug binding properties. <i>Biochimie</i> , 2015, 108, 40-47.	2.6	22
81	Chaotropicity: a key factor in product tolerance of biofuel-producing microorganisms. <i>Current Opinion in Biotechnology</i> , 2015, 33, 228-259.	6.6	160
82	Multiplication of microbes below 0.690 water activity: implications for terrestrial and extraterrestrial life. <i>Environmental Microbiology</i> , 2015, 17, 257-277.	3.8	131
83	Value of predictive bioinformatics in inherited metabolic diseases. <i>World Journal of Medical Genetics</i> , 2015, 5, 46.	1.0	5
84	The <i>Saccharomyces cerevisiae</i> quinone oxidoreductase Lot6p: stability, inhibition and cooperativity. <i>FEMS Yeast Research</i> , 2014, 14, 797-807.	2.3	9
85	Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, <i>Fasciola hepatica</i> . <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 744-749.	2.3	15
86	The two common polymorphic forms of human NRH quinone oxidoreductase 2 (NQO2) have different biochemical properties. <i>FEBS Letters</i> , 2014, 588, 1666-1672.	2.8	26
87	Purple sweet potato colour – a potential therapy for galactosemia?. <i>International Journal of Food Sciences and Nutrition</i> , 2014, 65, 391-393.	2.8	14
88	FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2163-2173.	3.8	56
89	The metastability of human UDP-galactose 4-epimerase (GALE) is increased by variants associated with type III galactosemia but decreased by substrate and cofactor binding. <i>Archives of Biochemistry and Biophysics</i> , 2014, 562, 103-114.	3.0	25
90	UDP-Galactose-4-Epimerase (GALE)., 2014, , 1449-1464.		2

#	ARTICLE	IF	CITATIONS
91	Cause or Effect: Which Genetic Changes Are Associated With Cancer?. <i>Gene, Cell and Tissue</i> , 2014, 1, .	0.2	0
92	Fragmentation of Neutral Amino Acids and Small Peptides by Intense, Femtosecond Laser Pulses. <i>Journal of the American Society for Mass Spectrometry</i> , 2013, 24, 1366-1375.	2.8	9
93	Comparison of dynamics of wildtype and V94M human UDP-galactose 4-epimerase A computational perspective on severe epimerase-deficiency galactosemia. <i>Gene</i> , 2013, 526, 318-324.	2.2	17
94	Effects of Alcohols and Compatible Solutes on the Activity of β -Galactosidase. <i>Applied Biochemistry and Biotechnology</i> , 2013, 169, 786-794.	2.9	38
95	Citrate synthase from the liver fluke <i>Fasciola hepatica</i> . <i>Parasitology Research</i> , 2013, 112, 2413-2417.	1.6	6
96	Triose phosphate isomerase from the blood fluke <i>Schistosoma mansoni</i> : Biochemical characterisation of a potential drug and vaccine target. <i>FEBS Letters</i> , 2013, 587, 3422-3427.	2.8	22
97	IQ-motif peptides as novel anti-microbial agents. <i>Biochimie</i> , 2013, 95, 875-880.	2.6	25
98	Differential expression of liver fluke β -tubulin isotypes at selected life cycle stages. <i>International Journal for Parasitology</i> , 2013, 43, 1133-1139.	3.1	15
99	Biochemical characterisation of triose phosphate isomerase from the liver fluke <i>Fasciola hepatica</i> . <i>Biochimie</i> , 2013, 95, 2182-2189.	2.6	27
100	In silico prediction of the effects of mutations in the human UDP-galactose 4-epimerase gene: Towards a predictive framework for type III galactosemia. <i>Gene</i> , 2013, 524, 95-104.	2.2	23
101	FhCaBP3: A <i>Fasciola hepatica</i> calcium binding protein with EF-hand and dynein light chain domains. <i>Biochimie</i> , 2013, 95, 751-758.	2.6	22
102	A universal measure of chaotropicity and kosmotropicity. <i>Environmental Microbiology</i> , 2013, 15, 287-296.	3.8	172
103	Misfolding of galactose 1-phosphate uridylyltransferase can result in type I galactosemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1279-1293.	3.8	44
104	Role of Arg228 in the Phosphorylation of Galactokinase: The Mechanism of GHMP Kinases by Quantum Mechanics/Molecular Mechanics Studies. <i>Biochemistry</i> , 2013, 52, 4858-4868.	2.5	22
105	The biology of habitat dominance; can microbes behave as weeds?. <i>Microbial Biotechnology</i> , 2013, 6, 453-492.	4.2	205
106	Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest. <i>Scientific Reports</i> , 2013, 3, 1770.	3.3	21
107	FhCaBP4: a <i>Fasciola hepatica</i> calcium-binding protein with EF-hand and dynein light chain domains. <i>Parasitology Research</i> , 2012, 111, 1707-1713.	1.6	19
108	A calcium-dependent interaction between calmodulin and the calponin homology domain of human IQGAP1. <i>Molecular and Cellular Biochemistry</i> , 2012, 371, 217-223.	3.1	11

#	ARTICLE	IF	CITATIONS
109	A plasma membrane Ca ²⁺ -ATPase (PMCA) from the liver fluke, <i>Fasciola hepatica</i> . <i>International Journal for Parasitology</i> , 2012, 42, 851-858.	3.1	9
110	LIAD-fs scheme for studies of ultrafast laser interactions with gas phase biomolecules. <i>Physical Chemistry Chemical Physics</i> , 2012, 14, 6289.	2.8	45
111	Plume characteristics and dynamics of UV and IR laser-desorbed oligonucleotides. <i>International Journal of Biological Macromolecules</i> , 2012, 50, 1081-1090.	7.5	2
112	Altered cofactor binding affects stability and activity of human UDP-galactose 4-epimerase: Implications for type III galactosemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1516-1526.	3.8	30
113	A novel calmodulin-like protein from the liver fluke, <i>Fasciola hepatica</i> . <i>Biochimie</i> , 2012, 94, 2398-2406.	2.6	13
114	The Molecular Dynamics of <i>Trypanosoma brucei</i> UDP-Galactose 4-Epimerase: A Drug Target for African Sleeping Sickness. <i>Chemical Biology and Drug Design</i> , 2012, 80, 173-181.	3.2	14
115	N-acetylgalactosamine Kinase: A Naturally Promiscuous Small Molecule Kinase. <i>Applied Biochemistry and Biotechnology</i> , 2012, 166, 57-63.	2.9	3
116	Galactokinases: Potential Biotechnological Applications as Biocatalysts. <i>Current Biotechnology</i> , 2012, 1, 148-154.	0.4	6
117	Biochemical analysis of the interactions of IQGAP1 C-terminal domain with CDC42. <i>World Journal of Biological Chemistry</i> , 2012, 3, 53.	4.3	16
118	In vivo and in vitro function of human UDP-galactose 4-epimerase variants. <i>Biochimie</i> , 2011, 93, 1747-1754.	2.6	18
119	Artemisinins act through at least two targets in a yeast model. <i>FEMS Yeast Research</i> , 2011, 11, 233-237.	2.3	19
120	Interaction of prothrombin with a phospholipid surface: evidence for a membrane-induced conformational change. <i>Molecular and Cellular Biochemistry</i> , 2011, 348, 109-115.	3.1	4
121	The <i>GAL</i> genetic switch: visualisation of the interacting proteins by split-GFP bimolecular fluorescence complementation. <i>Journal of Basic Microbiology</i> , 2011, 51, 312-317.	3.3	2
122	Structural and molecular biology of type I galactosemia: Disease-associated mutations. <i>IUBMB Life</i> , 2011, 63, 949-954.	3.4	34
123	The structural and molecular biology of type I galactosemia: Enzymology of galactose 1-phosphate uridylyltransferase. <i>IUBMB Life</i> , 2011, 63, n/a-n/a.	3.4	15
124	Increased Promiscuity of Human Galactokinase Following Alteration of a Single Amino Acid Residue Distant from the Active Site. <i>ChemBioChem</i> , 2011, 12, 2081-2087.	2.6	16
125	The role of the active site residues in human galactokinase: Implications for the mechanisms of GHMP kinases. <i>Bioorganic Chemistry</i> , 2011, 39, 120-126.	4.1	20
126	The interaction of IQGAPs with calmodulin-like proteins. <i>Biochemical Society Transactions</i> , 2011, 39, 694-699.	3.4	17

#	ARTICLE	IF	CITATIONS
127	IQ-motif selectivity in human IQGAP2 and IQGAP3: binding of calmodulin and myosin essential light chain. <i>Bioscience Reports</i> , 2011, 31, 371-379.	2.4	30
128	IR laser desorption of oligonucleotides. <i>European Physical Journal D</i> , 2010, 60, 163-169.	1.3	3
129	Experimental setup and first measurement of DNA damage induced along and around an antiproton beam. <i>European Physical Journal D</i> , 2010, 60, 209-214.	1.3	4
130	Liver fluke β -tubulin isotype 2 binds albendazole and is thus a probable target of this drug. <i>Parasitology Research</i> , 2010, 107, 1257-1264.	1.6	19
131	The biochemical basis of hereditary fructose intolerance. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 105-112.	3.6	87
132	A ligand predication tool based on modeling and reasoning with imprecise probabilistic knowledge. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 98, 45-54.	4.7	0
133	Hydrophobic substances induce water stress in microbial cells. <i>Microbial Biotechnology</i> , 2010, 3, 701-716.	4.2	118
134	Binding of serum albumin to the anthelmintic drugs albendazole, triclabendazole and their sulphoxides. <i>Veterinary Parasitology</i> , 2010, 171, 172-175.	1.8	15
135	Mechanistic studies on human N-acetylgalactosamine kinase. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2010, 25, 370-376.	5.2	13
136	Interactions of the 67 kDa laminin receptor and its precursor with laminin. <i>Bioscience Reports</i> , 2010, 30, 73-79.	2.4	14
137	Split-EGFP Screens for the Detection and Localisation of Protein-Protein Interactions in Living Yeast Cells. <i>Methods in Molecular Biology</i> , 2010, 638, 303-317.	0.9	6
138	The contribution of key hydrophobic residues in ecotin to enzyme-inhibitor complex stability. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2009, 24, 1207-1210.	5.2	4
139	DNA damage by low-energy ions. <i>Biochemical Society Transactions</i> , 2009, 37, 893-896.	3.4	16
140	Development of a novel mass spectrometric technique for studying DNA damage. <i>Biochemical Society Transactions</i> , 2009, 37, 905-909.	3.4	7
141	Serine Proteases in Bone Disease. <i>Current Rheumatology Reviews</i> , 2009, 5, 141-147.	0.8	1
142	Analysis of UDP-galactose 4-epimerase mutations associated with the intermediate form of type III galactosaemia. <i>Journal of Inherited Metabolic Disease</i> , 2008, 31, 108-116.	3.6	27
143	IQ motif selectivity in human IQGAP1: binding of myosin essential light chain and S100B. <i>Molecular and Cellular Biochemistry</i> , 2008, 318, 43-51.	3.1	21
144	Interactions between the budding yeast IQGAP homologue lgg1p and its targets revealed by a split-EGFP bimolecular fluorescence complementation assay. <i>Cell Biology International</i> , 2008, 32, 1318-1322.	3.0	6

#	ARTICLE	IF	CITATIONS
145	Functional domains of the human epididymal protease inhibitor, eppin. FEBS Journal, 2008, 275, 1742-1750.	4.7	21
146	Fasciola hepatica expresses multiple α - and β -tubulin isotypes. Molecular and Biochemical Parasitology, 2008, 159, 73-78.	1.1	48
147	Development and implementation of split-GFP-based bimolecular fluorescence complementation (BiFC) assays in yeast. Biochemical Society Transactions, 2008, 36, 479-482.	3.4	27
148	Detection and localisation of protein-protein interactions in <i>Saccharomyces cerevisiae</i> using a split-GFP method. Fungal Genetics and Biology, 2008, 45, 597-604.	2.1	18
149	The 67 kDa laminin receptor: structure, function and role in disease. Bioscience Reports, 2008, 28, 33-48.	2.4	155
150	Plume Image Profiling of UV Laser Desorbed Biomolecules. , 2008, , .		1
151	Formation of gas phase macromolecular targets by laser desorption from surfaces. Journal of Physics: Conference Series, 2008, 101, 012016.	0.4	3
152	Effects of low energy carbon ions on plasmid DNA. Journal of Physics: Conference Series, 2008, 101, 012012.	0.4	3
153	Detection of Protein-Protein Interactions Using Protein-Fragment Complementation Assays (PCA). Current Proteomics, 2007, 4, 17-27.	0.3	7
154	Damage to plasmid DNA induced by low energy carbon ions. Physics in Medicine and Biology, 2007, 52, 3729-3740.	3.0	30
155	Conformational changes to plasmid DNA induced by low energy carbon ions. Journal of Physics: Conference Series, 2007, 58, 355-358.	0.4	4
156	Characterisation of two calmodulin-like proteins from the liver fluke, <i>Fasciola hepatica</i> . Biological Chemistry, 2007, 388, 593-599.	2.5	16
157	Characterization of the <i>Saccharomyces cerevisiae</i> galactose mutarotase/UDP-galactose 4-epimerase protein, Gal10p. FEMS Yeast Research, 2007, 7, 366-371.	2.3	18
158	Coumarin-Based Inhibitors of Human NAD(P)H:Quinone Oxidoreductase-1. Identification, Structure-Activity, Off-Target Effects and In Vitro Human Pancreatic Cancer Toxicity. Journal of Medicinal Chemistry, 2007, 50, 6316-6325.	6.4	66
159	GHMP Kinases - Structures, Mechanisms and Potential for Therapeutically Relevant Inhibition. Current Enzyme Inhibition, 2007, 3, 77-94.	0.4	29
160	In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6246-6254.	2.2	33
161	The structural and molecular biology of type III galactosemia. IUBMB Life, 2006, 58, 83-89.	3.4	52
162	Functional analysis of disease-causing mutations in human UDP-galactose 4-epimerase. FEBS Journal, 2005, 272, 6170-6177.	4.7	43

#	ARTICLE	IF	CITATIONS
163	Molecular Structure of <i>Saccharomyces cerevisiae</i> Gal1p, a Bifunctional Galactokinase and Transcriptional Inducer. <i>Journal of Biological Chemistry</i> , 2005, 280, 36905-36911.	3.4	54
164	Molecular Structure of Human Galactokinase. <i>Journal of Biological Chemistry</i> , 2005, 280, 9662-9670.	3.4	94
165	Molecular Structure of Human Galactose Mutarotase. <i>Journal of Biological Chemistry</i> , 2004, 279, 23431-23437.	3.4	34
166	Galactokinase: structure, function and role in type II galactosemia. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 2471-2484.	5.4	88
167	Substrate Specificity and Mechanism from the Structure of <i>Pyrococcus furiosus</i> Galactokinase. <i>Journal of Molecular Biology</i> , 2004, 337, 387-398.	4.2	53
168	Functional analysis of disease-causing mutations in human galactokinase. <i>FEBS Journal</i> , 2003, 270, 1767-1774.	0.2	69
169	Glycosaminoglycans in human retinoblastoma cells: heparan sulfate, a modulator of the pigment epithelium-derived factor-receptor interactions. <i>BMC Biochemistry</i> , 2003, 4, 1.	4.4	32
170	Sugar recognition by human galactokinase. <i>BMC Biochemistry</i> , 2003, 4, 16.	4.4	40
171	Identification and characterisation of human aldose 1-epimerase. <i>FEBS Letters</i> , 2003, 543, 21-24.	2.8	43
172	Fine tuning the myosin motor: the role of the essential light chain in striated muscle myosin. <i>Biochimie</i> , 2003, 85, 639-645.	2.6	56
173	Gal3p and Gal1p interact with the transcriptional repressor Gal80p to form a complex of 1:1 stoichiometry. <i>Biochemical Journal</i> , 2002, 363, 515.	3.7	40
174	Gal3p and Gal1p interact with the transcriptional repressor Gal80p to form a complex of 1:1 stoichiometry. <i>Biochemical Journal</i> , 2002, 363, 515-520.	3.7	36
175	Kinetic analysis of yeast galactokinase: implications for transcriptional activation of the GAL genes. <i>Biochimie</i> , 2002, 84, 265-272.	2.6	52
176	DNA ligases in the repair and replication of DNA. <i>Mutation Research DNA Repair</i> , 2000, 460, 301-318.	3.7	150
177	Size and Charge Requirements for Kinetic Modulation and Actin Binding by Alkali 1-type Myosin Essential Light Chains. <i>Journal of Biological Chemistry</i> , 1999, 274, 18271-18277.	3.4	42
178	Structure of the adenylation domain of an NAD ⁺ -dependent DNA ligase. <i>Structure</i> , 1999, 7, 35-42.	3.3	84
179	Nucleotide sequence, heterologous expression and novel purification of DNA ligase from <i>Bacillus stearothermophilus</i> . <i>BBA - Proteins and Proteomics</i> , 1999, 1432, 413-418.	2.1	8
180	Functional domains of an NAD ⁺ -dependent DNA ligase 1 Edited by A. R. Fersht. <i>Journal of Molecular Biology</i> , 1999, 285, 73-83.	4.2	77

#	ARTICLE	IF	CITATIONS
181	The N-terminus of A1-type myosin essential light chains binds actin and modulates myosin motor function. FEBS Journal, 1998, 255, 654-662.	0.2	69
182	The rôle of the proline-rich region in A1-type myosin essential light chains: implications for information transmission in the actomyosin complex. FEBS Letters, 1997, 400, 31-36.	2.8	22